Biopharmas raising money in public or private financings.

Biopharmas raising money in public or private financings.

Biopharmas raising money in public or private financings.

BEIJING – After Suzhou, China-based Ascentage Pharma Group International launched a $53 million IPO on the Hong Kong Stock Exchange (HKEX) Monday, Tot Biopharm International Co. Ltd., also from Suzhou, and Sinomab Bioscience Ltd., of Hong Kong, will also debut on the bourse to reap as much as $87 million and $223.1 million, respectively, in the following two weeks.

Biopharmas raising money in public or private financings.

HONG KONG – Shanghai-based I-Mab Biopharma Co. Ltd. has filed for an IPO in the U.S., seeking to raise up to $100 million.

Biopharmas raising money in public or private financings.

Biopharmas raising money in public or private financings.

Roughly 40 years after Bio-Response launched the first-ever biotech IPO, three companies priced IPOs on Friday, riding a wave of momentum that has put 2019 into second place for the most IPO money raised in a single year. Only 2018's record $10.7 billion is beyond this year's total: 54 global IPOs raising $7.98 billion.